Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2023
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
The New England Journal of Medicine|October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 YearsPaolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Pageof 7